Edgewise Therapeutics, Inc. Common Stock Stock Prediction
AI-powered sentiment analysis and prediction trends for EWTX, updated each market day.
EWTX AI Sentiment
AI sees no strong directional signal for Edgewise Therapeutics, Inc. Common Stock stock over the next 10 market days.
Prediction date: April 10, 2026
Subscribers see precise scores, buy/sell targets, and full analytics.
About Edgewise Therapeutics, Inc. Common Stock
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is developing novel therapeutics for muscular dystrophies and serious cardiac conditions. The company's product candidates are Sevasemten, EDG-7500, EDG-003, and EDG-15400. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies, including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company's products are currently in different stages of their development, being developed to target key muscle proteins and modulators to address a broad array of muscle diseases.
Sector
Exchange
Market Cap
$3,595,707,863
Cap Tier
Employees
146
Headquarters
BOULDER, CO
Listed Since
March 26, 2021
Website
EWTX Sentiment Trend — Last 30 Predictions
Sentiment zones: Bullish · Neutral · Bearish
EWTX Volatility
Edgewise Therapeutics, Inc. Common Stock has shown high price volatility over the last 5 trading days. High volatility means larger price swings — this can present both opportunity and risk for traders.
